Eli Lilly and Company (NYSE:LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued ...

The stock's rise snapped a five-day losing streak.

Continue » Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the ... after a trial patient experienced a liver injury while taking it.

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

As long as you are willing to be patient, now may be an excellent time to add Eli Lilly stock to your portfolio. Don’t miss this second chance at a potentially lucrative opportunity Ever feel ...

Novo has also launched NovoCare, an online direct-to-patient pharmacy intended to ... With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate ...

Sales of Trulicity are also being hurt by patient switches to Mounjaro ... deeper to understand whether to buy, sell or hold Lilly’s stock. Lilly’s stock has risen 14.8% so far this year ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that ... Pfizer said it is ending work on the pill after a patient experienced a liver injury during the drug’s trial.

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in 2026.

Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non-opioid pain ...